169 related articles for article (PubMed ID: 16167036)
1. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.
Fisher RI
Clin Adv Hematol Oncol; 2005 Jul; 3(7):544-6. PubMed ID: 16167036
[No Abstract] [Full Text] [Related]
2. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
[No Abstract] [Full Text] [Related]
3. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI
Blood; 2003 Sep; 102(5):1606-12. PubMed ID: 12738671
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
[TBL] [Abstract][Full Text] [Related]
5. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
7. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
Persky DO; Unger JM; Spier CM; Stea B; LeBlanc M; McCarty MJ; Rimsza LM; Fisher RI; Miller TP;
J Clin Oncol; 2008 May; 26(14):2258-63. PubMed ID: 18413640
[TBL] [Abstract][Full Text] [Related]
11. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
[No Abstract] [Full Text] [Related]
12. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
13. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
[TBL] [Abstract][Full Text] [Related]
14. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
15. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma.
Derenzini E; Casadei B; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL
Br J Haematol; 2014 Aug; 166(4):625-8. PubMed ID: 24750128
[No Abstract] [Full Text] [Related]
17. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
[No Abstract] [Full Text] [Related]
19. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
20. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]